How India Exports Cladribine to the World

As of March 2026, the U.S. Food and Drug Administration (FDA) has approved several Abbreviated New Drug Applications (ANDAs) for Cladribine. Notably, on March 22, 2023, Apotex Corp. received approval for ANDA 218425 for Cladribine Tablets, 10 mg, deemed bioequivalent to EMD Serono's Mavenclad Tablets, 10 mg. The reference listed drug, Mavenclad, is protected by patents expiring between May 31, 2026, and November 23, 2038.

The presence of 50 active Indian exporters indicates a competitive landscape for Cladribine exports to the U.S. market. However, the existing patent protections may limit the immediate market entry of generic versions. Importantly, there are no current FDA import alerts specific to Cladribine, suggesting compliance with U.S. regulatory standards.

In the European Union, Cladribine is marketed under the brand name Mavenclad, authorized by the European Medicines Agency (EMA) on August 22, 2017, for the treatment of highly active relapsing multiple sclerosis. (ema.europa.eu) Additionally, Litak, another Cladribine-containing product, has been authorized since April 14, 2004, for the treatment of hairy-cell leukemia. (ema.europa.eu)

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA's approvals, ensuring that Cladribine products meet stringent EU Good Manufacturing Practice (GMP) requirements. These standards necessitate comprehensive quality assurance measures, including validation of manufacturing processes and rigorous quality control testing.

Cladribine is not listed in the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone the WHO Prequalification Programme. However, Cladribine's inclusion in major pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) underscores its recognized therapeutic value and establishes standardized quality benchmarks for its production and quality control.

In India, Cladribine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. As of March 2026, Cladribine is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it is not subject to government-mandated price ceilings. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

Cladribine's patent landscape is complex. In the U.S., key patents for Mavenclad are set to expire between May 31, 2026, and November 23, 2038. This extended patent protection period may delay the entry of generic competitors into the market. In the EU, similar patent protections are in place, affecting the market dynamics for generic Cladribine products.

1. FDA Approval of Apotex's Generic Cladribine Tablets: In March 2023, the FDA approved Apotex Corp.'s ANDA for Cladribine Tablets, 10 mg, marking a significant development in the availability of generic Cladribine in the U.S. market.

2. EMA's Safety Update on Cladribine: In September 2017, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for Cladribine-containing products, highlighting the potential risk of Progressive Multifocal Leukoencephalopathy (PML). (ema.europa.eu)

3. WHO's Inclusion of Cladribine in Pharmacopoeias: As of March 2026, Cladribine continues to be included in major pharmacopoeias, including the USP, BP, EP, and IP, reflecting its established therapeutic use and standardized quality requirements.

These developments underscore the evolving regulatory and market landscape for Cladribine, highlighting the importance of ongoing compliance with international standards and vigilance regarding safety updates.

Cladribine, an antineoplastic agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used for U.S.-approved APIs are solely sourced from China, as reported by the U.S. Pharmacopeia in October 2025. Such reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these vulnerabilities. In March 2026, the closure of the Strait of Hormuz, a critical maritime passage, led to significant delays in the shipment of raw materials, including those essential for pharmaceutical manufacturing. This event highlighted the fragility of supply chains dependent on specific geographic regions for critical inputs.

The export market for Cladribine from India is characterized by a moderate level of supplier concentration. The top five exporters account for 34.9% of the total export value, with RMPL Pharma LLP leading at a 16.0% share. This distribution suggests a relatively diversified supplier base, which can mitigate risks associated with over-reliance on a single exporter.

To further reduce dependency on specific suppliers and enhance supply chain resilience, the Indian government has implemented the Production Linked Incentive (PLI) scheme. This initiative aims to bolster domestic manufacturing of APIs and KSMs, thereby decreasing reliance on imports and promoting a more robust pharmaceutical supply chain.

Geopolitical tensions have recently led to significant disruptions in global shipping routes. In March 2026, the closure of the Strait of Hormuz halted maritime traffic, affecting the transportation of essential goods, including pharmaceutical products. This blockade resulted in increased shipping costs and delays, impacting supply chains worldwide.

Additionally, the Red Sea has experienced heightened security threats, leading major shipping lines to suspend transits through this critical corridor. These disruptions have forced rerouting of shipments, adding transit time and costs, and posing challenges to timely delivery of pharmaceutical products.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials to decrease reliance on imports.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to mitigate risks associated with geopolitical disruptions in key maritime corridors.

• Implement Robust Inventory Management: Maintain strategic stockpiles of essential materials to buffer against supply chain interruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to continuously assess and respond to geopolitical events that may impact the supply chain.

RISK_LEVEL: HIGH